Business Context and Reporting Period
This Form 8-K Current Report was filed by Marshall Edwards, Inc. (not Lite Strategy, Inc.) on May 2, 2011. The filing discloses the entry into a Material Definitive Agreement involving a private placement of equity securities. The company is incorporated in Delaware and headquartered in San Diego, California.
Key Financial Metrics and Transaction Details
The filing details a Securities Purchase Agreement with accredited investors. Key terms include:
- Common Stock Issuance: 835,217 shares sold at a purchase price of $1.333 per share.
- Warrant Issuance:
- Series A: Right to purchase up to 626,413 shares; initial exercise price $1.57.
- Series B: Right to purchase up to 2,165,534 shares; initial exercise price is the lower of $1.333 or 85% of the average trading price.
- Series C: Initially exercisable for zero shares, with a potential increase up to 16,000,000 shares if stock price falls below certain levels; initial exercise price $0.00000002.
- Placement Agent: Roth Capital Partners received warrants for 7% of the Common Shares and a cash fee equal to 7% of gross proceeds.
- Liquidity and Debt: The filing does not provide specific values for current cash flow, total debt, or liquidity ratios. Proceeds from the offering are intended to provide capital, but specific allocation is not detailed in this text.
Material Changes and Conditions
The transaction is subject to specific conditions, including:
- Stockholder Approval: Requires approval from Novogen Limited (majority stockholder), which will become effective 20 days after mailing a definitive information statement.
- Ownership Dilution: Upon issuance, Novogen's ownership will decrease from approximately 65.1% to 59.0%.
- Registration Rights: The Company must file a registration statement within 30 days of closing. Failure to do so triggers liquidated damages of 2% of the aggregate purchase price per month for unregistered securities.
- Lock-up Agreements: Novogen is locked up until December 24, 2011. Officers and directors are locked up for the earlier of 90 days after registration effectiveness or 13 months after closing.
Outlook, Risks, and Contingencies
Management commentary is limited to the terms of the agreement. Key risks and contingencies include:
- Anti-Dilution Provisions: Series A and B warrants have full ratchet anti-dilution protection if the company sells stock below the exercise price.
- Series C Contingency: If stockholder approval is not obtained by the time Series C warrants become exercisable, the company must pay cash in lieu of shares.
- Beneficial Ownership Limit: Holders are limited to owning a maximum of 9.99% of outstanding shares after exercise.
- Future Offerings: The company is restricted from making further equity offers for 13 months or 90 days post-registration, with limited exceptions.
Investor Verification Checklist
- Verify the closing date and actual gross proceeds received from the private placement.
- Confirm the status of the Registration Statement filing and its effectiveness date.
- Monitor the stock price to determine if Series C warrant share counts increase or if Series A/B exercise prices are adjusted.
- Check for the definitive information statement regarding the Novogen stockholder approval.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants not summarized here.